Drug Trial Radar · NCT00820027
Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)
Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
776
Actual
Start
Dec 15, 2008
Primary completion
Dec 13, 2010
Study completion Dec 14, 2010
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of Etoricoxib compared to placebo and ibuprofen in the treatment of postoperative pain associated with unilateral total knee replacement surgery. The hypotheses for this study were that the average pain intensity difference (at rest) in participants treated with Etoricoxib (120 mg, 90 mg) is superior to placebo, the average total daily dose of morphine in participants treated with Etoricoxib (120 mg, 90 mg) is less than in participants treated with placebo, and that Etoricoxib (120 mg, 90 mg) will be generally safe and well tolerated by participants treated for pain following total knee replacement orthopedic surgery.
Conditions
- Pain, Postoperative
Interventions
Etoricoxib 90 mgDrug
One 90 mg tablet once daily
Etoricoxib 120 mgDrug
Two 60 mg tablets once daily
Ibuprofen 600 mgDrug
One tablet three times daily
Matching Placebo for Etoricoxib 120 mgDrug
Two tablets once daily
Matching Placebo for Etoricoxib 90 mgDrug
One tablet once daily
Matching Placebo for IbuprofenDrug
One tablet three times daily
MorphineDrug
As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
OxycodoneDrug
5 mg as needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)Time frame: Baseline and Days 1-3
- Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)Time frame: Days 1-3
- Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac FailureTime frame: Up to 21 days
- Percentage of Participants With at Least One Edema-Related AETime frame: Up to 21 days
- Percentage of Participants With at Least One Hypertension-Related AETime frame: Up to 21 days
- Percentage of Participants With at Least One Opioid-Related AETime frame: Up to 21 days
- Percentage of Participants Who Discontinued Study Drug Due to an AETime frame: Up to 7 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.